Fluorodopa F 18

Chemical NameFluorodopa F 18
Dosage FormInjectable (intravenous; 15.5 MBq/mL to 308.2 MBq/mL (0.42 mCi/mL to 8.33 mCi/mL))
Drug ClassRadioactive diagnostic agents
SystemNervous
CompanyFeinstein
Approval Year2019

Indication

  • Fluorodopa F 18 is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Fluorodopa F 18 Prescribing Information 2019Feinstein